Your browser doesn't support javascript.
Progress in the risk assessment of hydroxychloroquine in frail elderly people.
Castagna, Alberto; Ruotolo, Giovanni; Manzo, Ciro.
  • Castagna A; Azienda Sanitaria Provinciale Catanzaro, Primary Care Departiment, Center for Cognitive Disorders and Dementia Catanzaro Italy.
  • Ruotolo G; Geriatric Unit General Hospital Azienda Ospedaliera Pugliese-Ciaccio di Catanzaro Catanzaro Italy.
  • Manzo C; Azienda Sanitaria Locale Napoli 3 Sud Internal and Geriatric Medicine Department - Gerontorheumatological Outpatient Clinic Poliambulatorio "Mariano Lauro" - Distretto Sanitario 59 Naples Italy.
Aging Med (Milton) ; 4(1): 53-57, 2021 Mar.
Article in English | MEDLINE | ID: covidwho-1130430
ABSTRACT
Hydroxychloroquine (HCQ) is an antimalarial drug also known to have anti-inflammatory and antiviral effects. The antiviral action of HCQ has been a point of interest for many researchers because of its mechanism of action and the potential use it could have during the current COVID-19 pandemic. However, HCQ can cause QT interval prolongation. The current therapies used in COVID-19 are changing as the pandemic develops. The aim of this article is to promote a validated risk score for QT prolongation in multidimensional assessment of COVID-19 patients, especially in elderly and polypathological patients.
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Language: English Journal: Aging Med (Milton) Year: 2021 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Language: English Journal: Aging Med (Milton) Year: 2021 Document Type: Article